12 slides from Grifols, S.a. Class A's earnings presentation, May 7, 2015
Slide 1: 1Q 2015 - Performance Summary
1Q 2015 - Performance Summary
Slide 2: Operational and Financial Highlights - 1Q 2015
Operational and Financial Highlights - 1Q 2015 Net profit up by +6.2% to Euros 128.5 million Income grows by +13.8% (+1.1% cc*) to Euros 908.4 million, driven by sales of alpha-1 antitrypsin, one of the main plasma proteins (Bioscience division) and by NAT technology diagnostic solutions (Diagnostic
Slide 3: Operational and Financial Highlights - 1Q 2015
Operational and Financial Highlights - 1Q 2015 Net financial debt of Euros 3,981 million, a ratio of 3.7 times EBITDA (3.3x cc) including cash of Euros 800 million. Additionally, Euros 400 million of undrawn facilities are available Strengthened R&D portfolio with the acquisition of 47.58% of the ca
Slide 4: Key financial figures
Key financial figures - 1Q 2015 4 In millions of euros except % and EPS 1Q 2015 1Q 2014 % Var NET REVENUE (NR) 908.4 798.0 13.8% GROSS PROFIT 49.7% 52.7% R&D 50.9 37.9 34.4% % NR 5.6% 4.7% EBITDA 280.0 270.2 3.6% % NR 30.8% 33.9% EBIT 236.4 223.9 5.6% % NR 26.0% 28.1% GROUP NET PROFIT 128.5 121.0 6.
Slide 5: Net revenue by division
Net revenue by division - 1Q 2015 5 In thousands of euros 1Q 2015 % of Net Revenues 1Q 2014 % of Net Revenues % Var % Var cc* BIOSCIENCE 681,027 75.0% 600,958 75.3% 13.3% 0.0% DIAGNOSTIC 172,561 19.0% 146,549 18.4% 17.7% 6.0% HOSPITAL 23,259 2.5% 24,262 3.0% (4.1%) (5.2%) RAW MATERIALS AND OTHERS 31
Slide 6: Net revenue by region
Net revenue by region - 1Q 2015 6 In thousands of euros 1Q 2015 % of Net Revenues 1Q 2014 % of Net Revenues % Var % Var cc* US + CANADA 567,112 62.4% 484,804 60.7% 17.0% 0.2% EU 170,997 18.8% 169,180 21.2% 1.1% (0.7%) R.O.W. 138,738 15.3% 117,785 14.8% 17.8% 6.9% SUBTOTAL 876,847 96.5% 771,769 96.7%
Slide 7: Profit & Loss account
Profit & Loss account - 1Q 2015 7 In thousands of euros 1Q 2015 1Q 2014 % Var NET REVENUE (NR) 908,384 797,998 13.8% COST OF SALES (457,282) (377,283) 21.2% GROSS PROFIT 451,102 420,715 7.2% % NR 49.7% 52.7% R&D (50,916) (37,895) 34.4% SG&A (163,825) (158,956) 3.1% OPERATING EXPENSES (214,741) (196,
Slide 8: Balance sheet (Assets)
Balance sheet (Assets) - 1Q 2015 8 March December 2015 2014 NON-CURRENT ASSETS 6,550,428 5,536,627 GOODWILL AND OTHER INTANGIBLE ASSETS 4,768,296 4,243,093 PROPERTY PLANT & EQUIPMENT 1,575,917 1,147,782 INVESTMENTS IN EQUITY ACCOUNTED INVESTEES 90,250 54,296 NON-CURRENT FINANCIAL ASSETS 33,930 9,011
Slide 9: Balance sheet (Equity & Liabilities)
Balance sheet (Equity & Liabilities) - 1Q 2015 9 March December 2015 2014 EQUITY 3,135,300 2,662,888 CAPITAL 119,604 119,604 SHARE PREMIUM RESERVE 910,728 910,728 RESERVES 1,558,605 1,088,337 TREASURY STOCK (69,252) (69,252) INTERIM DIVIDENDS (85,944) (85,944) CURRENT YEAR EARNINGS 128,490 470,253 O
Slide 10: Cash flow
Cash flow - 1Q 2015 10 In thousands of euros 1Q 2015 1Q 2014 GROUP PROFIT 128,490 120,973 DEPRECIATION AND AMORTIZATION 43,663 46,354 NET PROVISIONS (4,965) (196) OTHER ADJUSTMENTS AND OTHER CHANGES IN WORKING CAPITAL (36,125) 21,035 CHANGES IN INVENTORIES (39,195) (11,339) CHANGES IN TRADE RECEIVAB
Slide 11: Share Performance
Share Performance - 1Q 2015 GRIFOLS’ DAILY SHARE PRICE, CLASS A & CLASS B vs IBEX 35 BASE 100, from December 31, 2014 to March 31, 2015 Source: Infobolsa 11 Class B 11.1% Class A 20.7% IBEX-35 12.1%
Slide 12: Forward-looking statements
12 The facts and figures contained in this report which do not refer to historical data are “projections and forward looking statements”. The words and expressions like “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “try to achieve”, “estimate”, “future” and similar expres